Education, Science, Technology, Innovation and Life
Open Access
Sign In

Dupilumab for Recurrent Prurigo Nodularis: A Case Report and Review of the Literature

Download as PDF

DOI: 10.23977/medsc.2023.040105 | Downloads: 6 | Views: 364

Author(s)

Wei Jiang 1, Xueyong Wang 1, Nan Li 1, Zhiguo Xu 1

Affiliation(s)

1 The 78th Group Army Hospital of Chinese PLA, Mudanjiang, Heilongjiang, 157000, China

Corresponding Author

Wei Jiang

ABSTRACT

Prurigo nodularis (PN) is a chronic inflammatory skin disease that affects the quality of life of patients and is classified in the ICD-10 as a group of chronic lichen simplex and itchy skin diseases (ICD-10/L28) with an incidence of approximately 36.7-148.53 per 100,000 people. The pathogenesis of PN is closely related to type 2 inflammatory response. There are no standardized treatment guidelines for this disease, and traditional anti-pruritic treatment regimens often fail to control the vicious pruritic-scratch cycle in PN and have a poor safety profile. Traditional treatment options for PN include oral antihistamines, thalidomide, and topical hormones, calcium phosphatase inhibitors, and other treatments. However, traditional treatment options often suffer from poor pruritus control and high side effects. A patient with prurigo nodularis was admitted to our hospital who responded poorly to routine topical glucocorticoids and other drug therapies and relapsed after discharge from treatment. After readmission, the patient was successfully treated with dupilumab, a biological agent targeting interleukin-4/13. The patient's rash was significantly flattened, and the pruritus NRS score was significantly decreased. In this case, successful treatment of refractory PN with dupilumab could provide new ideas for treatment.

KEYWORDS

Prurigo nodularis; Dupilumab

CITE THIS PAPER

Wei Jiang, Xueyong Wang, Nan Li, Zhiguo Xu, Dupilumab for Recurrent Prurigo Nodularis: A Case Report and Review of the Literature. MEDS Clinical Medicine (2023) Vol. 4: 27-32. DOI: http://dx.doi.org/10.23977/medsc.2023.040105.

REFERENCES

[1] Kwatra S.G., Breaking the Itch-Scratch Cycle in Prurigo Nodularis. N Engl J Med, 2020. 382(8): p. 757-758.
[2] Garcovich, S., M. Maurelli, P. Gisondi, K. Peris, G. Yosipovitch, and G. Girolomoni, Pruritus as a Distinctive Feature of Type 2 Inflammation. Vaccines (Basel), 2021. 9(3).
[3] Labib A., T. Ju A. Vander Does, and G. Yosipovitch, Immunotargets and Therapy for Prurigo Nodularis. Immunotargets Ther, 2022. 11: p. 11-21.
[4] Wong L.S. and Y.T. Yen, Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment. Int J Mol Sci, 2022. 23(20).
[5] Williams K.A., A.H. Huang, M. Belzberg, and S.G. Kwatra, Prurigo nodularis: Pathogenesis and management. J Am Acad Dermatol, 2020. 83(6): p. 1567-1575.
[6] Elmariah S., B. Kim, T. Berger, S. Chisolm, S.G. Kwatra, N. Mollanazar, and G. Yosipovitch, Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol, 2021. 84(3): p. 747-760.
[7] Huang A.H., K.A. Williams, and S.G. Kwatra, Prurigo nodularis: Epidemiology and clinical features. J Am Acad Dermatol, 2020. 83(6): p. 1559-1565.
[8] Stander S., C. Zeidler, M. Pereira, J.C. Szepietowski, L. McLeod, S. Qin, N. Williams, T. Sciascia, and M. Augustin, Worst Itch Numerical Rating Scale for Prurigo Nodularis: A Psychometric Evaluation. J Eur Acad Dermatol Venereol, 2021.
[9] Yang T.B. and B.S. Kim, Pruritus in allergy and immunology. J Allergy Clin Immunol, 2019. 144(2): p. 353-360.
[10] Chiricozzi, A., M. Maurelli, N. Gori, G. Argenziano, C. De Simone, G. Calabrese, G. Girolomoni, and K. Peris, Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol, 2020. 83(1): p. 39-45.
[11] Holm, J.G., T. Agner, C. Sand, and S.F. Thomsen, Dupilumab for prurigo nodularis: Case series and review of the literature. Dermatol Ther, 2020. 33(2): p. e13222.
[12] Husein-ElAhmed, H. and M. Steinhoff, Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat, 2022. 33(3): p. 1547-1553.
[13] Cunha, I.M., I. Valadao, E. Gomes, and A. Marinho, Dupilumab: A Safe and Successful Treatment in Refractory Prurigo Nodularis. J Allergy Clin Immunol Pract, 2022. 10(5): p. 1365-1366.
[14] Fostini, A.C., G. Girolomoni, and G. Tessari, Prurigo nodularis: an update on etiopathogenesis and therapy. J Dermatolog Treat, 2013. 24(6): p. 458-62.
[15] Hanel, K.H., C. Cornelissen, B. Luscher, and J.M. Baron, Cytokines and the skin barrier. Int J Mol Sci, 2013. 14(4): p. 6720-45.
[16] Munoz-Bellido, F.J., E. Moreno, and I. Davila, Dupilumab: A Review of Present Indications and Off-Label Uses. J Investig Allergol Clin Immunol, 2022. 32(2): p. 97-115.
[17] Langan S.M., A.D. Irvine, and S. Weidinger, Atopic dermatitis. Lancet, 2020. 396(10247): p. 345-360.
[18] Szollosi A.G., A. Olah, E. Lisztes, Z. Griger, and B.I. Toth, Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk. Front Pharmacol, 2022. 13: p. 745658.
[19] Huang A.H., J.K. Canner, R. Khanna, S. Kang, and S.G. Kwatra, Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases. J Invest Dermatol, 2020. 140(2): p. 480-483 e4.
[20] Inui K., T. Ugajin, T. Namiki, and H. Yokozeki, Chronic prurigo: A retrospective study of 168 cases. J Dermatol, 2020. 47(3): p. 283-289.
[21] Kahremany S., L. Hofmann, A. Gruzman, and G. Cohen, Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch. Int J Mol Sci, 2020. 21(14).
[22] Beck K.M., E.J. Yang, S. Sekhon, T. Bhutani, and W. Liao, Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatol, 2019. 155(1): p. 118-120.
[23] Cevikbas F. and E.A. Lerner, Physiology and Pathophysiology of Itch. Physiol Rev, 2020. 100(3): p. 945-982.
[24] Miake S., G. Tsuji, M. Takemura, A. Hashimoto-Hachiya, Y.H. Vu, M. Furue, and T. Nakahara, IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis. Int J Mol Sci, 2019. 20(16).
[25] Ringkamp M., R.J. Schepers, S.G. Shimada, L.M. Johanek, T.V. Hartke, J. Borzan, B. Shim, R.H. LaMotte, and R.A. Meyer, A role for nociceptive, myelinated nerve fibers in itch sensation. J Neurosci, 2011. 31(42): p. 14841-9.
[26] Wong L.S., Y.T. Yen, S.H. Lin, and C.H. Lee, IL-17A Induces Endothelin-1 Expression through p38 Pathway in Prurigo Nodularis. J Invest Dermatol, 2020. 140(3): p. 702-706 e2.
[27] Stander S., G. Yosipovitch, J.P. Lacour, F.J. Legat, C. Paul, A. Reich, K. Chaouche, F. Ahmad, and C. Piketty, Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol, 2022. 36(10): p. 1820-1825.
[28] Sonkoly E., A. Muller, A.I. Lauerma, A. Pivarcsi, H. Soto, L. Kemeny, H. Alenius, M.C. Dieu-Nosjean, S. Meller, J. Rieker, M. Steinhoff, T.K. Hoffmann, T. Ruzicka, A. Zlotnik, and B. Homey, IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol, 2006. 117(2): p. 411-7.
[29] Raap U., K. Wichmann, M. Bruder, S. Stander, B. Wedi, A. Kapp, and T. Werfel, Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol, 2008. 122(2): p. 421-3.
[30] Mashaghi A., A. Marmalidou, M. Tehrani, P.M. Grace, C. Pothoulakis, and R. Dana, Neuropeptide substance P and the immune response. Cell Mol Life Sci, 2016. 73(22): p. 4249-4264.
[31] Matsumura S., M. Terao, H. Murota, and I. Katayama, Th2 cytokines enhance TrkA expression, upregulate proliferation, and downregulate differentiation of keratinocytes. J Dermatol Sci, 2015. 78(3): p. 215-23.
[32] Agrawal D., K. Sardana, S.R. Mathachan, M. Bhardwaj, A. Ahuja, and S. Jain, A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications. J Cosmet Dermatol, 2022. 21(9): p. 4009-4015.
[33] Ju T., A. Labib, A. Vander Does, and G. Yosipovitch, Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: A case series. J Am Acad Dermatol, 2022. 87(2): p. 400-403.
[34] Li H., Z. Zhang, H. Zhang, Y. Guo, and Z. Yao, Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol, 2021. 61(3): p. 324-338.
[35] Peng C., C. Li, Y. Zhou, Q. Wang, P. Xie, T. Li, and P. Hao, Tofacitinib for Prurigo Nodularis: A Case Report. Clin Cosmet Investig Dermatol, 2022. 15: p. 503-506.
[36] Pereira M.P., C. Zeidler, and S. Stander, Improvement of chronic nodular prurigo with baricitinib. J Eur Acad Dermatol Venereol, 2022. 36(6): p. e486-e488.
[37] Yin M., R. Wu, J. Chen, and X. Dou, Successful treatment of refractory prurigo nodularis with baricitinib. Dermatol Ther, 2022. 35(8): p. e15642.
[38] Fachler T., S. Maria Faitataziadou, and V. Molho-Pessach, Dupilumab for pediatric prurigo nodularis: A case report. Pediatr Dermatol, 2021. 38(1): p. 334-335. 

Downloads: 3912
Visits: 170414

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.